Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Medical Guidelines
• Cancer Therapeutics

Background:

• The National Comprehensive Cancer Network (NCCN) develops evidence-based guidelines for cancer care.
• Non-Small Cell Lung Cancer (NSCLC) is a major cause of cancer-related mortality worldwide.
• Treatment decisions for advanced NSCLC increasingly rely on identifying actionable molecular biomarkers.

Purpose of the Study:

• To present the updated NCCN Clinical Practice Guidelines for Non-Small Cell Lung Cancer (NSCLC).
• To focus on treatment recommendations for advanced or metastatic NSCLC.
• To highlight targeted therapies informed by recent FDA approvals and clinical data for patients with specific molecular biomarkers.

Main Methods:

• The NCCN Guidelines panel reviewed recent clinical data and FDA approvals.
• Recommendations were updated for the management of NSCLC.
• The focus was on treatment strategies for advanced or metastatic disease with actionable molecular biomarkers.

Main Results:

• Updated recommendations for targeted therapies in advanced or metastatic NSCLC are provided.
• The guidelines incorporate the latest clinical evidence and regulatory approvals.
• Specific molecular biomarkers guide the selection of recommended targeted treatments.

Conclusions:

• The NCCN Guidelines offer current, evidence-based recommendations for NSCLC management.
• Targeted therapies, guided by molecular biomarkers, are crucial for advanced NSCLC.
• These updated guidelines support optimal treatment selection for patients with NSCLC.